{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:23:30Z","timestamp":1768350210097,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Antidementia drugs (cholinesterase inhibitors and memantine) are still widely prescribed despite their controversial effects and 2011 guidelines that no longer encourage their prescription. The objective was to assess which factors remained determinants of antidementia drug prescriptions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross\u2010sectional study was performed in 2013. Patients suffering from dementia, aged 65 and over, identified in the French national health insurance database were included. Because we anticipated a high correlation between age, comorbidities, and health care use, we first identified the patients' health status by a latent class analysis. Second, we performed adjusted logistic regression models. The explanatory variables were patients' health status, gender, prescription of nonpharmacological treatments (physical and speech therapies), prescription of psychotropic drugs, and access to health care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 3873 patients included, 38% received antidementia drugs. Three latent classes of patients with different health status were identified. Patients with poor health status received significantly fewer antidementia drugs (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001). Patients with speech therapy or antidepressant drugs received significantly more antidementia drugs (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001), whereas patients with physical therapy received significantly fewer antidementia drugs (<jats:italic>P<\/jats:italic> = .006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Antidementia drugs were less likely to be prescribed for patients with poor health status. This result is encouraging for these frail patients who are more vulnerable to the adverse effects of treatments. At the same time, this result encourage targeting specifically patients in good health status for the use of a decision aid, in an attempt to limit prescriptions by involving patients and families.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4921","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T04:20:06Z","timestamp":1581999606000},"page":"444-452","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Determinants of antidementia drug prescription in patients older than 65: A latent class analysis"],"prefix":"10.1002","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-7016","authenticated-orcid":false,"given":"Mathilde","family":"Fran\u00e7ois","sequence":"first","affiliation":[{"name":"INSERM, Centre de Recherche en Epid\u00e9miologie et Sant\u00e9 des Populations, UMR1018, h\u00f4pital Paul Brousse Universit\u00e9 Paris Saclay  Villejuif Cedex France"},{"name":"D\u00e9partement de m\u00e9decine g\u00e9n\u00e9rale, Facult\u00e9 des sciences de la sant\u00e9 Simone Veil Universit\u00e9 Versailles\u2010Saint\u2010Quentin\u2010en\u2010Yvelines  Montigny le Bretonneux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Sicsic","sequence":"additional","affiliation":[{"name":"INSERM, Centre de Recherche en Epid\u00e9miologie et Sant\u00e9 des Populations, UMR1018, h\u00f4pital Paul Brousse Universit\u00e9 Paris Saclay  Villejuif Cedex France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Pelletier\u2010Fleury","sequence":"additional","affiliation":[{"name":"INSERM, Centre de Recherche en Epid\u00e9miologie et Sant\u00e9 des Populations, UMR1018, h\u00f4pital Paul Brousse Universit\u00e9 Paris Saclay  Villejuif Cedex France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.11.007"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0083-y"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0481-7"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0446-x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-122140"},{"key":"e_1_2_10_7_1","first-page":"CD009132","article-title":"Cholinesterase inhibitors for mild cognitive impairment","volume":"9","author":"Russ TC","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000157"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170371"},{"key":"e_1_2_10_10_1","unstructured":"HAS (Haute Autorit\u00e9 de Sant\u00e9). Maladie d'Alzheimer et maladies apparent\u00e9es: diagnostic et prise en charge.http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2011-12\/recommandation_maladie_d_alzheimer_et_maladies_apparentees_diagnostic_et_prsie_en_charge.pdf"},{"key":"e_1_2_10_11_1","unstructured":"APA Work Group on Alzheimer's Disease and other Dementias RabinsPV RovnerBW RummansT SchneiderLS TariotPN. Guideline watch (october 2014): practice guideline for the treatment of patients with Alzheimer's disease and other dementias.http:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/alzheimerwatch.pdf"},{"key":"e_1_2_10_12_1","unstructured":"Dementia: supporting people with dementia and their carers in health and social care|Guidance and guidelines.https:\/\/www.nice.org.uk\/guidance\/cg42\/chapter\/1-Guidance#interventions-for-noncognitive-symptoms-and-behaviour-that-challenges-in-people-with-dementia"},{"key":"e_1_2_10_13_1","unstructured":"Cochrane for Clinicians: Exercise Programs for Older Patients with Dementia\u2014American Family Physician. [cited 2017 March 10].Available from:http:\/\/www.aafp.org\/afp\/2014\/0901\/p287.html"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1044\/1058-0360(2012\/11-0137)"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283339496"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamainternmed.1022"},{"issue":"4","key":"e_1_2_10_17_1","first-page":"161","article-title":"Le m\u00e9dicament: un outil de communication?","volume":"103","author":"Dupr\u00e9\u2010L\u00e9v\u00eaque D","year":"2002","journal-title":"G\u00e9rontologie Soci\u00e9t\u00e9"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3917\/pos.403.0213"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3917\/jgem.135.0263"},{"issue":"6","key":"e_1_2_10_20_1","first-page":"557","article-title":"Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta\u2010analysis","volume":"169","author":"Lanct\u00f4t KL","year":"2003","journal-title":"CMAJ\u2014Can Med Assoc J\u2014J Assoc Medicale Can"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aprim.2015.01.016"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12730"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2013.11.001"},{"key":"e_1_2_10_24_1","first-page":"1","article-title":"L'accessibilit\u00e9 potentielle localis\u00e9e (APL): une nouvelle mesure de l'accessibilit\u00e9 aux m\u00e9decins g\u00e9n\u00e9ralistes lib\u00e9raux","volume":"174","author":"Bardet M","year":"2012","journal-title":"Quest D\u00e9conomie Sant\u00e9"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2010.06.003"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2017.07.008"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-0994"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02552.x"},{"key":"e_1_2_10_29_1","first-page":"CD006489","article-title":"Exercise programs for people with dementia","volume":"4","author":"Forbes D","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1249\/JSR.0000000000000332"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2015.09.001"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4062"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005247"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12488"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12455"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-016-0434-6"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13702"},{"key":"e_1_2_10_38_1","unstructured":"M\u00e9dicaments rembours\u00e9s par l'Assurance Maladie.https:\/\/www.data.gouv.fr\/fr\/datasets\/medicaments-rembourses-par-lassurance-maladie\/"},{"key":"e_1_2_10_39_1","unstructured":"Sondage \u201cLes m\u00e9decins face aux pratiques d'actes injustifi\u00e9s\u201d\u2014F\u00e9d\u00e9ration Hospitali\u00e8re de France (FHF).http:\/\/www.fhf.fr\/Actualite\/A-la-Une\/Sondage-Les-medecins-face-aux-pratiques-d-actes-injustifies"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4921","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T17:58:21Z","timestamp":1694023101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1002\/pds.4921"],"URL":"https:\/\/doi.org\/10.1002\/pds.4921","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"2019-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}